NCT05859997View on ClinicalTrials.gov

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

NAEnrolling by invitationINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

May 27, 2024

Study Completion Date

May 27, 2025

Conditions
Systemic Lupus Erythematosus (SLE)Sjogren's SyndromeSystemic SclerosisInflammatory MyopathyANCA Associated Systemic VasculitisAntiphospholipid Syndrome
Interventions
BIOLOGICAL

BRL-301

Single dose of Allogeneic Anti-CD19 CAR T cells will be infused

Trial Locations (1)

200433

Shanghai ChangZheng hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter